• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SIGA Technologies Inc.

    6/24/22 4:05:38 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SIGA alert in real time by email
    SC 13G 1 tm2219342d1_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

      

    Under the Securities Exchange Act of 1934 

     

    SIGA Technologies, Inc.

    (Name of Issuer)

     

     

    Common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

    826917106

    (CUSIP Number)

     

     

    June 14, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the following box to designate the rule pursuant to which the Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 826917106
     
      1.

    Names of Reporting Persons

    D. E. Shaw & Co., L.P.

     

         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
           
      3. SEC Use Only
         
      4.

    Citizenship or Place of Organization

    Delaware

         

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

         
          6.

    Shared Voting Power

    3,633,285

             
          7.

    Sole Dispositive Power

    -0-

             
          8.

    Shared Dispositive Power

    3,634,392

             
      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,634,392

         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11.

    Percent of Class Represented by Amount in Row (9)

    5.0%

         
      12.

    Type of Reporting Person (See Instructions)

    IA, PN

               

     

     

     

    CUSIP No. 826917106
     
      1.

    Names of Reporting Persons

    David E. Shaw

         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
           
      3. SEC Use Only
         
      4.

    Citizenship or Place of Organization

    United States

         

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

         
          6.

    Shared Voting Power

    3,633,285

             
          7.

    Sole Dispositive Power

    -0-

             
          8.

    Shared Dispositive Power

    3,634,392

             
      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,634,392

         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11.

    Percent of Class Represented by Amount in Row (9)

    5.0%

         
      12.

    Type of Reporting Person (See Instructions)

    IN

               

     

     

     

    Item 1.
      (a) Name of Issuer
       

      SIGA Technologies, Inc.

       
      (b) Address of Issuer's Principal Executive Offices
       

      31 East 62nd Street

      New York, NY 10065

       
    Item 2.
      (a) Name of Person Filing
       

      D. E. Shaw & Co., L.P.

      David E. Shaw

       
      (b) Address of Principal Business Office or, if none, Residence
       

      The business address for each reporting person is:

      1166 Avenue of the Americas, 9th Floor

      New York, NY 10036

       
      (c) Citizenship
       

      D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.

      David E. Shaw is a citizen of the United States of America.

       
      (d) Title of Class of Securities
       

      Common stock, par value $0.0001 per share

       
      (e) CUSIP Number
       

      826917106

       
    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable

     

    Item 4.

    Ownership

     

    As of June 14, 2022:

     

    (a) Amount beneficially owned:
       
     

    D. E. Shaw & Co., L.P.:

    3,634,392 shares

    This is composed of (i) 2,104,754 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 1,361,378 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 134,053 shares in the name of D. E. Shaw Composite Portfolios, L.L.C., and (iv) 34,207 shares under the management of D. E. Shaw Investment Management, L.L.C.

         
     

    David E. Shaw:

    3,634,392 shares

    This is composed of (i) 2,104,754 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 1,361,378 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 134,053 shares in the name of D. E. Shaw Composite Portfolios, L.L.C., and (iv) 34,207 shares under the management of D. E. Shaw Investment Management, L.L.C.

         
    (b) Percent of class:  
      D. E. Shaw & Co., L.P.: 5.0%
      David E. Shaw: 5.0%

     

     

     

     

    (c)Number of shares to which the person has:
    (i)Sole power to vote or to direct the vote:
      D. E. Shaw & Co., L.P.: -0- shares
      David E. Shaw: -0- shares   

     

    (ii)Shared power to vote or to direct the vote:

      D. E. Shaw & Co., L.P.:

    3,633,285 shares

      David E. Shaw:

    3,633,285 shares

     

    (iii)Sole power to dispose or to direct the disposition of:
      D. E. Shaw & Co., L.P.: -0- shares   
      David E. Shaw: -0- shares   

     

    (iv)Shared power to dispose or to direct the disposition of:

      D. E. Shaw & Co., L.P.:

    3,634,392 shares

      David E. Shaw:

    3,634,392 shares

      

    David E. Shaw does not own any shares directly. By virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw Oculus Portfolios, L.L.C., and D. E. Shaw Composite Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C., and by virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw Oculus Portfolios, L.L.C., and D. E. Shaw Composite Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 3,633,285 shares, and the shared power to dispose or direct the disposition of 3,634,392 shares, the 3,634,392 shares as described above constituting 5.0% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 3,634,392 shares.

      

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

    Not Applicable

     

    Item 10. Certification

    By signing below, each of D. E. Shaw & Co., L.P. and David E. Shaw certify that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.

     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. A Power of Attorney, dated March 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, is attached hereto.

     

    Dated: June 24, 2022

     

      D. E. Shaw & Co., L.P.
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Chief Compliance Officer
         

     

      David E. Shaw
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Attorney-in-Fact for David E. Shaw

     

     

     

    Get the next $SIGA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SIGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SIGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive VP & CFO Luckshire Daniel J converted options into 24,193 shares and covered exercise/tax liability with 12,346 shares, increasing direct ownership by 5% to 275,064 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    7/2/25 9:03:24 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Scientific Officer Hruby Dennis E converted options into 32,258 shares and covered exercise/tax liability with 10,467 shares, increasing direct ownership by 13% to 191,047 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    7/2/25 8:58:34 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Keane John M

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    6/11/25 4:34:21 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    SEC Filings

    View All

    SEC Form 10-Q filed by SIGA Technologies Inc.

    10-Q - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    8/5/25 4:53:57 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    8/5/25 4:06:53 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    6/12/25 4:18:33 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30Corporate Update Conference Call Today at 4:30 PM ET SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025. "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second qu

    8/5/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-173

    7/29/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Reports Financial Results for Three Months Ended March 31, 2025

    Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of approximately $6 million marks what we expe

    5/8/25 4:05:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/1/24 3:54:12 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SIGA Technologies Inc. (Amendment)

    SC 13G/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/14/23 4:42:47 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    6/24/22 4:05:38 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Financials

    Live finance-specific insights

    View All

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30Corporate Update Conference Call Today at 4:30 PM ET SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025. "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second qu

    8/5/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-173

    7/29/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Reports Financial Results for Three Months Ended March 31, 2025

    Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of approximately $6 million marks what we expe

    5/8/25 4:05:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Leadership Updates

    Live Leadership Updates

    View All

    SIGA Appoints Retired General John M. Keane to its Board of Directors

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003. He is a foreign policy and national security expert who serves as an advisor to presidents, cabinet officials, members of congress, international leaders, CEOs, and business leaders. He also provide

    3/18/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Names Larry Miller General Counsel

    NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. "With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA's continued success and growth strategies forward," said Diem Nguyen, Chief Executive Officer.  "Larry will be instrumental in helping us expand our reach on a global scale and maximize the ben

    3/25/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. "The appointment of Diem Nguyen as our new CEO marks a significant milestone for SIGA as we continue to expand our partnerships with governments across the world in global health security initiatives and medical countermeasure preparedness," said Josep

    1/22/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care